A PHP Error was encountered

Severity: Warning

Message: fopen(/var/lib/php/sessions/ci_session8o396jmkb17kq3g9006sd5lgss7ak5bs): Failed to open stream: No space left on device

Filename: drivers/Session_files_driver.php

Line Number: 177

Backtrace:

File: /var/www/html/index.php
Line: 316
Function: require_once

A PHP Error was encountered

Severity: Warning

Message: session_start(): Failed to read session data: user (path: /var/lib/php/sessions)

Filename: Session/Session.php

Line Number: 137

Backtrace:

File: /var/www/html/index.php
Line: 316
Function: require_once

A PHP Error was encountered

Severity: Warning

Message: file_get_contents(https://...@gmail.com&api_key=61f08fa0b96a73de8c900d749fcb997acc09): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests

Filename: helpers/my_audit_helper.php

Line Number: 143

Backtrace:

File: /var/www/html/application/helpers/my_audit_helper.php
Line: 143
Function: file_get_contents

File: /var/www/html/application/helpers/my_audit_helper.php
Line: 209
Function: simplexml_load_file_from_url

File: /var/www/html/application/helpers/my_audit_helper.php
Line: 3098
Function: getPubMedXML

File: /var/www/html/application/controllers/Detail.php
Line: 574
Function: pubMedSearch_Global

File: /var/www/html/application/controllers/Detail.php
Line: 488
Function: pubMedGetRelatedKeyword

File: /var/www/html/index.php
Line: 316
Function: require_once

A PHP Error was encountered

Severity: Warning

Message: Attempt to read property "Count" on bool

Filename: helpers/my_audit_helper.php

Line Number: 3100

Backtrace:

File: /var/www/html/application/helpers/my_audit_helper.php
Line: 3100
Function: _error_handler

File: /var/www/html/application/controllers/Detail.php
Line: 574
Function: pubMedSearch_Global

File: /var/www/html/application/controllers/Detail.php
Line: 488
Function: pubMedGetRelatedKeyword

File: /var/www/html/index.php
Line: 316
Function: require_once

Biomarker-driven targeted therapy in patients with recurrent platinum-resistant epithelial ovarian cancer (BRIGHT): protocol for an open-label, multicenter, umbrella study. | LitMetric

AI Article Synopsis

  • The study focuses on improving outcomes for patients with platinum-resistant, recurrent ovarian cancer by testing a biomarker-driven combination of therapies including PARP inhibitors, immune checkpoint inhibitors, and chemotherapy.
  • The BRIGHT Trial is a phase II study that plans to enroll 160 patients from 11 centers in China, assigning them to three experimental treatment arms based on specific genomic and immunologic markers.
  • Patient treatment will continue until their disease progresses or they experience severe side effects, with a thorough documentation of any adverse events throughout the study.

Article Abstract

Background: Platinum-resistant, recurrent ovarian cancer has an abysmal prognosis with limited treatment options. Poly-(ADP-ribose)-polymerase (PARP), angiogenesis, and immune checkpoint inhibitors might improve the outcomes of platinum-resistant, recurrent ovarian cancer, but accurate patient selections for those therapies remain a significant clinical challenge.

Primary Objective: To evaluate the efficacy and safety of biomarker-driven combinatorial therapies of pamiparib, tislelizumab, bevacizumab, and nab-paclitaxel in platinum-resistant, recurrent ovarian cancer.

Study Hypothesis: A precision medicine combination of PARP inhibitors, anti-angiogenic therapy, immunotherapy, and chemotherapy will improve disease outcomes of platinum-resistant, recurrent ovarian cancer by accounting for genomic and immunologic features.

Trial Design: The BRIGHT Trial is a prospective, open-label, multicenter, phase II, umbrella study planning to enroll 160 patients with serous, endometrioid, or clear cell platinum-resistant, recurrent ovarian cancer from 11 clinical centers in China. Patients are assigned to one of three experimental arms based on biomarkers. Patients with mutations will receive pamiparib plus bevacizumab (arm 1, n=40) regardless of CD8 tumor-infiltrating lymphocytes count. Patients with wild-type () and ≥3 CD8 tumor-infiltrating lymphocytes count will receive the combination of tislelizumab, bevacizumab, and nab-paclitaxel (arm 2, n=50), while patients with <3 CD8 tumor-infiltrating lymphocytes count will receive bevacizumab plus dose-dense nab-paclitaxel (arm 3, n=50). After completing patient enrollment in arm 2, another 20 patients with ≥3 CD8 tumor-infiltrating lymphocytes count will be included as an arm 2 expansion. Treatment will continue until disease progression or intolerable toxicity, and all adverse events will be recorded.

Major Inclusion/exclusion Criteria: Eligible patients include those aged ≥18 with serous, endometrioid, or clear cell ovarian cancer, platinum-resistant recurrence, and Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.

Primary Endpoint: Objective response rate (ORR) assessed by the investigators by the RECIST 1.1 criteria.

Sample Size: 160 patients.

Estimated Dates For Completing Accrual And Presenting Results: Recruitment is estimated to be completed by 2024 and results may be published by 2027.

Trial Registration: ClinicalTrials.gov: NCT05044871.

Download full-text PDF

Source
http://dx.doi.org/10.1136/ijgc-2024-005351DOI Listing

Publication Analysis

Top Keywords

ovarian cancer
20
platinum-resistant recurrent
20
recurrent ovarian
20
open-label multicenter
8
umbrella study
8
outcomes platinum-resistant
8
tislelizumab bevacizumab
8
bevacizumab nab-paclitaxel
8
will receive
8
tumor-infiltrating lymphocytes
8

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!